Physician profile
Arvind G Modak
NPI 1215975255
$2,980.27
in general payments reported to CMS, 2019-2025
27 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $871 · 2021: $822 · 2022: $255 · 2024: $199 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $877.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $489.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $284.20 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $203.82 | 2020-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $193.36 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $157.49 | 2019-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $129.70 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.65 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $71.26 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.45 | 2021-2024 | |
| Medtronic, INC. | $52.81 | 2025 | Synchromedii |
| Shield Therapeutics INC | $44.21 | 2024-2025 | |
| Abbvie INC. | $37.65 | 2021-2022 | |
| Eisai INC. | $35.53 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.46 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.60 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $27.43 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.15 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $18.62 | 2019 | |
| Glaxosmithkline, LLC. | $16.32 | 2025 | Arexvy, Shingrix |
| Corcept Therapeutics | $15.87 | 2025 | Korlym |
| Arbor Pharmaceuticals, INC. | $15.87 | 2021 | |
| Insulet Corporation | $15.34 | 2025 | Omnipod |
| Paratek Pharmaceuticals, INC. | $15.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.15 | 2025 | Jardiance |
| Biogen, INC. | $14.71 | 2021 | |
| Allergan, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Modak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.